Article
GRAIL Announces Topline Results For NHS-Galleri Trial; Primary Endpoint Of Statistically Significant Combined Stage III-IV Reduction Was Not Met
The Primary Endpoint of Statistically Significant Combined Stage III-IV Reduction Was Not Met, However A Favorable Trend Was Observed Over Time
GRAIL Announces U.S. Sales Force Expansion Based on Strong NHS-Galleri and PATHFINDER 2 Trial Results
Comments
- No comments yet. Be the first to comment!